Sepsis News and Research

Latest Sepsis News and Research

Harvard scientists to further advance blood-cleansing technology for treating sepsis

The Wyss Institute for Biologically Inspired Engineering at Harvard University announced today that it was awarded a $9.25 million contract from the Defense Advanced Research Projects Agency to further advance a blood-cleansing technology developed at the Institute with prior DARPA support, and help accelerate its translation to humans as a new type of sepsis therapy.

26 Mar 2013

Eritoran drug does not reduce risk of death in patients with severe sepsis

Administration of the drug eritoran to patients with severe sepsis and septic shock failed to demonstrate a significant effect on reducing all-cause 28-day mortality or 1-year mortality, compared with placebo, according to a study in the March 20 issue of JAMA.

20 Mar 2013

Transfusion of older blood adversely affects patients undergoing cardiac surgery or critical care

Transfusion of donated blood more than three weeks old results in impaired blood vessel function, a new study of hospital patients shows.

11 Mar 2013

New rapid laboratory test successful in identifying GBS colonization in pregnant women

A more rapid laboratory test for pregnant women to detect potentially deadly Group B strep (GBS) has been successful at identifying GBS colonization in six and a half hours, according to the results of a study from The University of Texas Health Science Center at Houston (UTHealth).

11 Mar 2013

CALHM1 protein controls sense of taste, finds study

In collaboration with other research institutions, a Feinstein Institute for Medical Research investigator discovered a new protein that controls the sense of taste. The findings are published in the March issue of Nature.

7 Mar 2013

Study shows how fish oils help lower blood pressure via vasodilation at ion channels

Omega-3 fatty acids found in oily fish may have diverse health-promoting effects, potentially protecting the immune, nervous, and cardiovascular systems.

6 Mar 2013

Accenture supports Unified Clinical Organization to improve care coordination, patient outcomes

The Unified Clinical Organization, an innovative care improvement model from Trinity Health, is improving care coordination, patient outcomes and advancing standardization of care practices with support from Accenture.

6 Mar 2013

Researchers identify mechanisms that connect variety of diseases linked with inflammation

A study led by researchers at Boston University School of Medicine (BUSM) has identified epigenetic mechanisms that connect a variety of diseases associated with inflammation.

3 Mar 2013

Cubist receives FDA QIDP designation for ceftolozane/tazobactam to treat HABP/ VABP, cUTI

Cubist Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration (FDA) has designated the company's late-stage antibiotic candidate, ceftolozane/tazobactam, as a Qualified Infectious Disease Product (QIDP) for the indications of Hospital-Acquired Bacterial Pneumonia (HABP)/Ventilator-Associated Bacterial Pneumonia (VABP) and Complicated Urinary Tract Infections (cUTI).

1 Mar 2013

One in three ventilated people with ALI shows substantial PTSD symptoms

One in three people who survived stays in an intensive care unit (ICU) and required use of a mechanical ventilator showed substantial post-traumatic stress disorder (PTSD) symptoms that lasted for up to two years, according to a new Johns Hopkins study of patients with acute lung injury.

26 Feb 2013

Xellia to develop new antibiotics effective against multi-drug resistant Gram-negative bacteria

Xellia Pharmaceuticals, a fully integrated specialty pharmaceutical company focusing on the global anti-infective market, announced today that it is developing new antibiotics effective against multi-drug resistant (MDR), Gram-negative bacteria.

26 Feb 2013

Thermo Fisher Scientific launches Brilliance GBS Agar

Thermo Fisher Scientific Inc., the world leader in serving science, today announced the launch of Brilliance GBS Agar for the testing of Group B streptococci (GBS) during pregnancy.

From Thermo Fisher Scientific Inc. 26 Feb 2013

Scientists uncover atomic structure of dermcidin

An international team of scientists has discovered how an important natural antibiotic called dermcidin, produced by our skin when we sweat, is a highly efficient tool to fight tuberculosis germs and other dangerous bugs.

22 Feb 2013

FDA approves new vial size for CSL Behring’s Privigen to treat primary immunodeficiency

CSL Behring today announced that the United States Food and Drug Administration has approved a 40 g (400 mL) vial size for Privigen, immune globulin intravenous [human].

21 Feb 2013

UCB seeks FDA and EMA marketing authorization for Cimzia to treat active psoriatic arthritis

UCB announced today two new regulatory filings with the US Food and Drug Administration (FDA) and with the European Medicines Agency (EMA) to extend the marketing authorization for Cimzia (certolizumab pegol) for the treatment of adult patients with active psoriatic arthritis (PsA) and for adult patients with active axial spondyloarthritis (axSpA).

20 Feb 2013

Risk factors for invasive candidiasis in infants clarified

A combination of exposure to broad-spectrum antibiotics and having a platelet count below 50,000/mm3 significantly increases a low-to-normal–weight infant’s chance for developing invasive candidiasis, report researchers.

19 Feb 2013

Combining synthetic and natural toxins could disarm cancer, drug-resistant bacteria

Cancer researchers from Rice University suggest that a new man-made drug that's already proven effective at killing cancer and drug-resistant bacteria could best deliver its knockout blow when used in combination with drugs made from naturally occurring toxins.

13 Feb 2013

Symposium to discuss new techniques for assessing risk of acute kidney injury

Leading critical care experts will discuss new techniques for assessing risk of acute kidney injury (AKI) at an educational symposium to be held at the Eighteenth International Conference on Continuous Renal Replacement Therapies (CRRT) in San Diego.

11 Feb 2013

Celgene receives FDA approval for POMALYST to treat multiple myeloma

Celgene Corporation today announced the U.S. Food and Drug Administration (FDA) has approved POMALYST brand therapy (pomalidomide) for patients with multiple myeloma who have received at least two prior therapies including lenalidomide and bortezomib and have demonstrated disease progression on or within 60 days of completion of the last therapy.

10 Feb 2013

Feeding human breast milk to very-low-birth-weight infants reduces risk of sepsis and NICU costs

Feeding human breast milk to very-low-birth-weight infants greatly reduces risk for sepsis and significantly lowers associated neonatal intensive care unit (NICU) costs, according to a study by Rush University Medical Center researchers.

6 Feb 2013

Sepsis News and Research

Latest Sepsis News and Research

Harvard scientists to further advance blood-cleansing technology for treating sepsis

Eritoran drug does not reduce risk of death in patients with severe sepsis

Transfusion of older blood adversely affects patients undergoing cardiac surgery or critical care

New rapid laboratory test successful in identifying GBS colonization in pregnant women

CALHM1 protein controls sense of taste, finds study

Study shows how fish oils help lower blood pressure via vasodilation at ion channels

Accenture supports Unified Clinical Organization to improve care coordination, patient outcomes

Researchers identify mechanisms that connect variety of diseases linked with inflammation

Cubist receives FDA QIDP designation for ceftolozane/tazobactam to treat HABP/ VABP, cUTI

One in three ventilated people with ALI shows substantial PTSD symptoms

Xellia to develop new antibiotics effective against multi-drug resistant Gram-negative bacteria

Thermo Fisher Scientific launches Brilliance GBS Agar

Scientists uncover atomic structure of dermcidin

FDA approves new vial size for CSL Behring’s Privigen to treat primary immunodeficiency

UCB seeks FDA and EMA marketing authorization for Cimzia to treat active psoriatic arthritis

Risk factors for invasive candidiasis in infants clarified

Combining synthetic and natural toxins could disarm cancer, drug-resistant bacteria

Symposium to discuss new techniques for assessing risk of acute kidney injury

Celgene receives FDA approval for POMALYST to treat multiple myeloma

Feeding human breast milk to very-low-birth-weight infants reduces risk of sepsis and NICU costs

The future of automation: Machine learning–driven hepatocyte and organoid counting

From street to lab: Advancing controlled substance testing with handheld Raman and FTIR

Reimagining light scattering for biotherapeutics

Sepsis News and Research

Latest Sepsis News and Research

The future of automation: Machine learning–driven hepatocyte and organoid counting

From street to lab: Advancing controlled substance testing with handheld Raman and FTIR

Reimagining light scattering for biotherapeutics

Newsletters you may be interested in